Samannodi Mohammed S, Zhao Andrew, Hasbun Rodrigo
Department of Internal Medicine, McGovern Medical School at UT Health, Houston, TX, USA.
Family Medicine Residency, La Crosse - Mayo Clinic, La Crosse, WI, USA.
Am J Case Rep. 2018 Nov 20;19:1378-1381. doi: 10.12659/AJCR.911269.
BACKGROUND Neurocysticercosis is a Taenia solium infection which utilizes the tapeworm as a vector and humans as a definitive host and causes development of cystic lesions in the central nervous system. The current established medical therapy is albendazole with praziquantel as a secondary agent, but results can be mixed depending on each patient and their form of neurocysticercosis. CASE REPORT We present a case pertaining to a young female patient diagnosed with single parenchymal neurocysticercosis based on clinical and diagnostic findings. This case was unique in the sense that ivermectin, another antiparasitic agent, was used as monotherapy with significant improvement in the patient's clinical presentation and radiological findings. CONCLUSIONS Despite current guidelines recommending use of albendazole with or without praziquantel for neurocysticercosis, our case (as well as 4 other cases documented in the recent past) suggest a possible use of ivermectin as potential therapy for neurocysticercosis. We recommend continued research regarding other cases of ivermectin use in similar patients and even comparison studies with albendazole with or without praziquantel in terms of efficacy and side effects in order to better treat this international endemic.
神经囊尾蚴病是一种由猪带绦虫引起的感染，猪带绦虫作为传播媒介，人类作为终宿主，可导致中枢神经系统出现囊性病变。目前既定的药物治疗是使用阿苯达唑，吡喹酮作为二线药物，但治疗结果因患者个体及其神经囊尾蚴病的类型而异。病例报告：我们报告一例年轻女性患者，根据临床和诊断结果被诊断为单发实质性神经囊尾蚴病。该病例的独特之处在于，使用了另一种抗寄生虫药物伊维菌素进行单一治疗，患者的临床表现和影像学检查结果有显著改善。结论：尽管目前的指南推荐使用阿苯达唑（加或不加吡喹酮）治疗神经囊尾蚴病，但我们的病例（以及最近记录的其他4例病例）表明，伊维菌素可能可用于治疗神经囊尾蚴病。我们建议继续研究伊维菌素在类似患者中的其他应用病例，甚至进行伊维菌素与加或不加吡喹酮的阿苯达唑在疗效和副作用方面的对比研究，以便更好地治疗这种全球性地方病。
